B

Betta Pharmaceuticals Co Ltd
SZSE:300558

Watchlist Manager
Betta Pharmaceuticals Co Ltd
SZSE:300558
Watchlist
Price: 46.69 CNY 0.06% Market Closed
Market Cap: 19.6B CNY

Betta Pharmaceuticals Co Ltd
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Betta Pharmaceuticals Co Ltd
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
B
Betta Pharmaceuticals Co Ltd
SZSE:300558
EPS (Diluted)
ÂĄ0
CAGR 3-Years
30%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
EPS (Diluted)
ÂĄ0
CAGR 3-Years
20%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
EPS (Diluted)
ÂĄ4
CAGR 3-Years
-1%
CAGR 5-Years
9%
CAGR 10-Years
17%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
EPS (Diluted)
ÂĄ1
CAGR 3-Years
26%
CAGR 5-Years
4%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
EPS (Diluted)
ÂĄ2
CAGR 3-Years
25%
CAGR 5-Years
-5%
CAGR 10-Years
1%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
EPS (Diluted)
ÂĄ9
CAGR 3-Years
N/A
CAGR 5-Years
241%
CAGR 10-Years
N/A
No Stocks Found

Betta Pharmaceuticals Co Ltd
Glance View

Market Cap
19.6B CNY
Industry
Pharmaceuticals

Betta Pharmaceuticals Co Ltd., established in 2003, is a dynamic player in China's rapidly evolving pharmaceutical landscape. The company made its mark with a particular focus on the research, development, production, and sale of innovative oncology drugs. Its flagship product, icotinib, a breakthrough therapy for non-small cell lung cancer, propelled Betta Pharmaceuticals into the spotlight, underpinning their pursuit of excellence in targeted cancer treatment. By capitalizing on expertise in small molecule drug discovery, Betta Pharmaceuticals transformed from a bold idea into a critical partner for healthcare providers, offering proprietary products that serve unmet medical needs across China and beyond. Driving its business model is a robust pipeline fueled by an ongoing commitment to research and innovation. Betta Pharmaceuticals thrives on its biodiverse R&D programs which are facilitated through collaborations with world-class research institutes and industry partners. The company's revenues predominantly flow from sales of its own branded oncology drugs, supplemented by royalty streams from licensing agreements. Their approach blends a careful balance of keen scientific inquiry with commercial acumen, as Betta continually reinvests in clinical trials and regulatory approvals to bring new drugs to market. Thus, the company's ability to blend innovation with practical application keeps it well-positioned amid the competitive and ever-evolving global pharmaceutical arena.

Intrinsic Value
58.56 CNY
Undervaluation 20%
Intrinsic Value
Price
B

See Also

What is Betta Pharmaceuticals Co Ltd's EPS (Diluted)?
EPS (Diluted)
0.7 CNY

Based on the financial report for Sep 30, 2025, Betta Pharmaceuticals Co Ltd's EPS (Diluted) amounts to 0.7 CNY.

What is Betta Pharmaceuticals Co Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-12%

Over the last year, the EPS (Diluted) growth was -35%. The average annual EPS (Diluted) growth rates for Betta Pharmaceuticals Co Ltd have been 30% over the past three years , -12% over the past five years .

Back to Top